181 related articles for article (PubMed ID: 9316039)
1. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French Multicenter Octreotide Study Group.
Warnet A; Harris AG; Renard E; Martin D; James-Deidier A; Chaumet-Riffaud P
Neurosurgery; 1997 Oct; 41(4):786-95; discussion 796-7. PubMed ID: 9316039
[TBL] [Abstract][Full Text] [Related]
2. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
[TBL] [Abstract][Full Text] [Related]
3. Sustained improvement in vision in a recurrent growth hormone secreting macroadenoma during treatment with octreotide in the absence of marked tumour shrinkage.
Lindsay JR; Harding JA; Ellis PK; Sheridan B; Atkinson AB
Pituitary; 2003; 6(4):209-14. PubMed ID: 15237932
[TBL] [Abstract][Full Text] [Related]
4. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
5. The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas.
Warnet A; Timsit J; Chanson P; Guillausseau PJ; Zamfirescu F; Harris AG; Derome P; Cophignon J; Lubetzki J
J Neurosurg; 1989 Nov; 71(5 Pt 1):687-90. PubMed ID: 2809722
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
9. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
10. Chronic somatostatin analog administration in patients with alpha-subunit-secreting pituitary tumors.
Katznelson L; Oppenheim DS; Coughlin JF; Kliman B; Schoenfeld DA; Klibanski A
J Clin Endocrinol Metab; 1992 Nov; 75(5):1318-25. PubMed ID: 1358910
[TBL] [Abstract][Full Text] [Related]
11. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
Abe T; Lüdecke DK
Eur J Endocrinol; 2001 Aug; 145(2):137-45. PubMed ID: 11454508
[TBL] [Abstract][Full Text] [Related]
12. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
[TBL] [Abstract][Full Text] [Related]
13. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
14. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
15. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients.
Chanson P; Weintraub BD; Harris AG
Ann Intern Med; 1993 Aug; 119(3):236-40. PubMed ID: 8323093
[TBL] [Abstract][Full Text] [Related]
16. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
Lundin P; Edén Engström B; Karlsson FA; Burman P
AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
[TBL] [Abstract][Full Text] [Related]
17. Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide.
Chanson P; Warnet A
Metabolism; 1992 Sep; 41(9 Suppl 2):62-5. PubMed ID: 1518435
[TBL] [Abstract][Full Text] [Related]
18. The role of octreotide (Sandostatin) in non-growth hormone-, non-thyroid-stimulating hormone-, and non-prolactin-secreting adenomas.
Warnet A
Metabolism; 1992 Sep; 41(9 Suppl 2):59-61. PubMed ID: 1325596
[TBL] [Abstract][Full Text] [Related]
19. Treatment of thyrotropin-secreting pituitary adenomas with octreotide.
Shimatsu A; Murabe H; Kamoi K; Suzuki Y; Nakao K
Endocr J; 1999 Feb; 46(1):113-23. PubMed ID: 10426575
[TBL] [Abstract][Full Text] [Related]
20. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).
Warnet A; Lajeunie E; Gelbert F; Duet M; Chanson P; Cophignon J; Harris AG
Acta Endocrinol (Copenh); 1991 Apr; 124(4):487-91. PubMed ID: 2031445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]